<DOC>
	<DOCNO>NCT01163201</DOCNO>
	<brief_summary>This unique dose-escalation trial titrate dose umbilical cord blood ( UCB ) Treg CD3+ Teff cell goal infuse many CD3+ Teff cell possible without confer grade II-IV acute graft-versus-host disease ( GVHD ) . In study , investigator propose add UCB Treg UCB CD3+ Teff cell two TCD UCB donor unit goal transplant many CD3+ Teff cell possible without reintroduce risk acute GVHD . The investigator hypothesize Treg permit reintroduction CD3+ Teff cell provide bridge await HSC T cell recovery long term . The co-infusion Treg prevent GVHD without need prolong pharmacologic immunosuppression .</brief_summary>
	<brief_title>T-Regulatory Cell CD3 Depleted Double Umbilical Cord Blood Transplantation Hematologic Malignancies</brief_title>
	<detailed_description>Based prior study , first patient start low dose combination ( 3 x 10^6/kg Treg 3 x 10^6/kg CD3+ Teff cell ) . One patient enter level minimum 35 day observe patient prior move next dose level . ( 1 ) If GVHD occur , `` successful step '' , CD3+ Teff cell dose increase next high level next patient ; ( 2 ) If GVHD occur , `` fail step '' , Treg dose increase next high level next patient . It would take minimum 5 ( GVHD ) maximum 9 patient ( GVHD observe level ) complete Treg : CD3+ Teff cell combination . An additional 10 patient enrol verify reflect optimal combination evaluate safety profile .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Only patient require double umbilical cord blood ( UCB ) transplant consider study . UCB Requirements Three UCB unit require one Treg production two UCB transplant . The unrelated UCB donor must 46/6 HLAA , B , DRB1 match recipient ( HLA match use molecular technique : A B antigen level resolution DR allele level resolution ) . Suitable UCB unit select accord University Of Minnesota UCB Graft Selection Algorithm . Suitable UCB unit must ABO match . Disease Criteria : Patients age 18 55 year Acute Myeloid Leukemia : morphologically persistent disease representative bone marrow aspirate sample ≤ 10 % blast least 1 cycle chemotherapy ( patient refuse disqualify alternative protocol ) , 3rd high complete remission ( CR ) . Acute Lymphocytic Leukemia : morphologically persistent disease representative bone marrow aspirate sample ≤ 10 % blast least 1 cycle chemotherapy , 3rd high CR Chronic Myelogenous Leukemia Blast Crisis : ≤10 % residual blast bone marrow aspirate least 1 cycle induction chemotherapy combination tyrosine kinase inhibitor ( TKI ) Refractory Anemia Excess Blasts : ( ≤ 10 % ) representative bone marrow aspirate sample blast 1 cycle induction chemotherapy . If treat hypomethylating agent , patient eligible blast count ≤ 10 % 4 cycle evidence stable progressive disease least 2 cycle . Chronic Myeloproliferative Disease Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma , Marginal Zone BCell Lymphoma Follicular Lymphoma : disease must refractory least two chemotherapy regimen chemotherapy sensitive residual nodal disease ≥ 5 cm Lymphoplasmacytic Lymphoma , MantleCell Lymphoma , Prolymphocytic Leukemia : disease must refractory least two chemotherapy regimen chemotherapy sensitive residual nodal disease ≥ 5 cm Large Cell NonHodgkin 's Lymphoma : disease must refractory least two chemotherapy regimen chemotherapy sensitive residual nodal disease ≥ 5 cm Lymphoblastic Lymphoma , Burkitt 's Lymphoma , HighGrade NHL : disease must refractory least two chemotherapy regimen chemotherapy sensitive residual nodal disease ≥ 5 cm Performance Status , Age , Organ Function Adequate performance status define Karnofsky score ≥ 80 % Adequate organ function define : Renal : creatinine &lt; 2.0 mg/dL , Hepatic : bilirubin , AST/ALT , ALP &lt; 5 x upper limit normal , Pulmonary function : DLCOcorr &gt; 50 % normal , Cardiac : leave ventricular ejection fraction &gt; 45 % Voluntary write informed consent sign performance studyrelated procedure part normal medical care Available medically suitable HLAidentical relate donor Active infection time transplantation ( include active infection Aspergillus mold within 30 day ) History HIV infection Pregnant breast feeding . The agent use study may teratogenic fetus information excretion agent breast milk . Females childbearing potential must blood test urine study within 14 day prior registration rule pregnancy Prior myeloablative transplant within last 6 month Extensive prior therapy include &gt; 12 month alkylator therapy &gt; 6 month alkylator therapy extensive radiation Patients receive Y90 ibritumomab ( Zevalin ) I131 tositumomab ( Bexxar ) part salvage therapy ( eligible myeloablative umbilical cord blood transplant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>